Document:

<PAGE>   1
CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. Sections 200.800(b)(4), 200.83
and 240.24b-2

                                                                   EXHIBIT 10.64

                             FIRST AMENDMENT TO THE

              GENOMIC DATABASE COLLABORATION AND LICENSE AGREEMENT

Dear Mr. Gessler:

        This letter will serve as an amendment to the Genomic Database
Collaboration and License Agreement ("Agreement"), dated December 30, 1998,
between Procter & Gamble Pharmaceuticals Inc. ("P&GP") and Gene Logic Inc.
("Gene Logic"). Except as modified below, all terms and conditions of the
Agreement are incorporated into and made part of this amendment as though
expressly set forth herein.

         The Parties desire to amend the Agreement to specify the Consumer Price
Index ("CPI") that will be utilized to adjust the annual rate of payment for
each Scientific FTE. Accordingly, the Parties agree to amend the Paragraph 8.3
of the Agreement as follows (where bold text constitutes modified language):

         8.3      Research Support.

                  (a)      During the Research Term, P&GP shall provide Gene
                           Logic with financial support for the Research
                           Programs for Gene Logic's Scientific FTEs at a rate
                           of [***] per Scientific FTE. The Scientific FTE
                           payment rate payable pursuant to this Section 8.3(a)
                           shall be reevaluated annually on each anniversary of
                           the Effective Date and adjusted in proportion to the
                           percentage increase for the 12-month period ending in
                           November of that year in the Consumer Price Index of
                           all urban consumers as provided by the U.S. Bureau of
                           Labor Statistics. THE CONSUMER PRICE INDEX USED WILL
                           BE THAT FOR THE WASHINGTON-BALTIMORE, DC-MD-VA-WV
                           AREA, UNLESS MODIFIED BY THE U.S. BUREAU OF LABOR
                           STATISTICS. The number of Scientific FTEs for each
                           year of the Research Term will be set forth in the
                           applicable Research Plan; provided that such research
                           funding shall not support fewer than the number of
                           Scientific FTEs specified in Section 2.2 in any one
                           year period during the Research Term or at such lower
                           level as the parties may mutually agree taking into
                           account the work to be accomplished pursuant to the
                           Research Plans.

 *** CONFIDENTIAL TREATMENT REQUESTED

<PAGE>   2
        If you approve of the above amendment, please indicate your acceptance
by signing and dating where indicated below, and returning a signed original to
P&GP. The other signed original should be retained for your files.

<TABLE>
<S>                                                 <C>
ACCEPTED:                                            ACCEPTED:

GENE LOGIC INCORPORATED                              PROCTER & GAMBLE PHARMACEUTICALS, INC.

By  /s/ Mark D. Gessler                              By  /s/ Bruce L. Byrnes
   -----------------------------------------            ---------------------------------------
   Mark D. Gessler                                      Bruce L. Byrnes
   President and Chief Executive Officer                President, Global Health Care and
                                                        Corporate New Ventures
                                                        The Procter & Gamble Company

Date     February 1, 2000                            Date    January 28, 2000
     ---------------------------------------              -------------------------------------
</TABLE><PAGE>   1
CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. Sections 200.800(b)(4), 200.83
and 240.24b-2

                                                                   EXHIBIT 10.65

                             SECOND AMENDMENT TO THE

              GENOMIC DATABASE COLLABORATION AND LICENSE AGREEMENT

In consideration for the mutual promises, covenants and conditions contained
herein, by signing below, GENE LOGIC INC. ("Gene Logic") and PROCTER & GAMBLE
PHARMACEUTICALS, INC. ("P&GP") agree to amend the Genomic Database Collaboration
and License Agreement, dated as of December 30, 1998, between Gene Logic and
P&GP (the "Collaboration Agreement") as follows:

1.       All capitalized terms used herein and not defined herein shall have the
         meanings given such terms in the Collaboration Agreement.

2.       Pursuant to Section 2.6, P&GP elects to select [***] Gene Products from
         the Research Program in [***] as Gene Targets for the consideration of
         [***] per Gene Product as provided in Section 8.4. [***] of such Gene
         Products will be identified within 30 days of the date of signature of
         this amendment, and the remaining [***] Gene Products will be
         identified within a reasonable time thereafter. P&GP shall pay Gene
         Logic a total of [***] for such [***] Gene Products selected as Gene
         Targets by wire transfer prior to June 30, 2000.

3.       Pursuant to Section 2.5, P&GP and Gene Logic agree that the Research
         Program in [***] is terminated as of June 30, 2000. Accordingly,
         Section 2.1 is amended insofar as collaborative work going forward will
         be directed towards the [***] Program. Additionally, Section 2.2 is
         amended to provide that with respect to the portion of the Research
         Term commencing on July 1, 2000, the research support at Gene Logic
         shall not be fewer than [***] Scientific FTEs and those Scientific FTEs
         will be assigned to work in the area of [***]. Consistent with this
         amendment, pursuant to Section 8.3(a), the Research Plan for the
         collaboration is hereby amended to reflect the decrease from [***] to
         [***] FTEs to be supported by P&GP.

4.       P&GP and Gene Logic agree that the technology access and database fee
         under Section 8.2(b) for the period from July 1, 2000 through December
         31, 2001, which fee shall be paid on December 30, 2001, shall be
         reduced to [***]. Nothing herein is intended to modify the amount due
         under Section 8.2(a), which fee shall be paid on June 30, 2000.

5.       Except as expressly amended herein, the Collaboration Agreement remains
         in full force and effect.

The parties hereby agree to the above stated amendment.

<TABLE>
<S>                                                 <C>
GENE LOGIC INC.                                      PROCTER & GAMBLE PHARMACEUTICALS, INC.

By:  /s/ Mark D. Gessler                             By:  /s/ Bruce L. Byrnes
     ---------------------------------------              ---------------------------------------------------------

Printed Name:  Mark D. Gessler                       Printed Name:   Bruce L. Byrnes
              ------------------------------                        -----------------------------------------------

Title:  President and CEO                            Title:  President, Global Health Care & Corporate New Ventures
        ------------------------------------                -------------------------------------------------------

Date: June 28, 2000                                  Date: June 29, 2000
      --------------------------------------               --------------------------------------------------------
</TABLE>

[***] CONFIDENTIAL TREATMENT REQUESTED<PAGE>   1
CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. Sections 200.800(b)(4), 200.83
and 240.24b-2

                                                                   EXHIBIT 10.66

                              SETTLEMENT AGREEMENT

1.       INTRODUCTION OF THE PARTIES

         This agreement (the "Agreement") is made as of June 16, 2000 (the
         "Effective Date") by and between:

         1.1.     Gene Logic Inc., a Delaware corporation,
                  having its registered office at 708 Quince Orchard Road,
                  Gaithersburg, Maryland 20878,
                  United States of America,
                  (hereinafter referred to as "Gene Logic")

                  and

         1.2.     Aventis CropScience GmbH, a corporation duly organized under
                  the laws of Germany,
                  having its registered office at Industriepark Hochst - K 607,
                  Briiningstrasse 50,
                  65926 Frankfurt am Main,
                  Germany,
                  (hereinafter referred to as "Aventis")

         The foregoing companies may be referred to individually as a "Party" or
         collectively as the "Parties".

2.       PREAMBLE

         WHEREAS Gene Logic and Aventis (formerly Hoechst Schering AgrEvo GmbH)
         have entered on June 30, 1998 into a collaborative effort (the
         "Collaboration Agreement") directed towards the development of a
         Research Database (as defined in the Collaboration Agreement) for
         identification of genetic targets for the development and
         commercialization of Agricultural Products (as defined in the
         Collaboration Agreement);

         WHEREAS, the Parties wish to terminate the Collaboration Agreement by
         mutual agreement on the terms and subject to the conditions set forth
         in this Agreement.

         NOW THEREFORE, in consideration of the foregoing premises and the
         mutual promises covenants and conditions contained herein, the
         sufficiency and adequacy of such consideration being hereby
         acknowledged, and in settlement of all disputes that have arisen
         between the Parties in relation to the Collaboration Agreement, it is
         hereby agreed as follows:

3.       TERMINATION OF THE COLLABORATION AGREEMENT

         The Parties mutually agree to terminate the Collaboration Agreement as
         of the Effective Date under the following conditions:

<PAGE>   2

3.1.     Aventis pays Gene Logic an amount of [***] at the latest on June 30,
         2000 provided that Aventis has received all the Samples, protocols and
         data described in Section 3.6 by that date.

3.2.     No other payments, fees or financial support will be due by Aventis to
         Gene Logic arising under or related to the Collaboration Agreement or
         its termination under this Agreement;

3.3.     Aventis waives its rights to maintain an exclusive license to the
         Research Database following the termination of the Collaboration
         Agreement;

3.4.     Aventis is released from the reporting obligation set forth in Section
         5.7 of the Collaboration Agreement on the fifth (5th) anniversary of
         the Effective Date of this Agreement;

3.5.     Aventis shall discontinue use of the Gene Logic Software and the
         Research Database and shall (i) cooperate with Gene Logic to terminate
         the encrypted link to Gene Logic's computer system and (ii) promptly
         deliver to Gene Logic copies of the Gene Logic Software;

3.6.     Gene Logic shall discontinue use of Samples and related experimental
         protocols provided to Gene Logic by Aventis and shall promptly return
         such Samples, cored READS fragments that have been sequenced and clones
         thereof and protocols as well as all data (meaning in this context all
         [***], all information under the following [***] to Aventis. All
         Samples, protocols and data will be shipped to Aventis and also
         transferred on CDs at the latest on June 30, 2000.

         The cored READS fragments that have been sequenced and the clones
         thereof will be shipped to AVENTIS as soon as possible but in no event
         later than thirty (30) days form the Effective Date. In addition, Gene
         Logic will present the cored READS fragments coded with the READS
         Fragment ID number as set forth in the aforesaid data.

4.       EFFECT OF THE SETTLEMENT

         The Parties acknowledge and agree that this Agreement is intended as a
         compromise of all disputes between the Parties. This Agreement shall
         not be construed as an admission with, respect to any issue or dispute
         among the Parties in connection with the Collaboration Agreement or its
         termination under this Agreement.

                                      -2-

*** CONFIDENTIAL TREATMENT REQUESTED

<PAGE>   3

5.       PRESS RELEASE

         The Parties agree that a press release announcing the termination of
         the Collaboration Agreement will be prepared by Gene Logic and will be
         subject to the approval of Aventis, which approval will not
         unreasonably be withheld.

6.       GENERAL PROVISIONS

         6.1      Notices

                  Any notice or other communication required or permitted to be
                  given by any Party under this Agreement shall be given in
                  writing and shall be (i) personally delivered, (ii) delivered
                  by a nationally recognized overnight courier, or (iii)
                  delivered by certified mail, postage prepaid, return receipt
                  requested or (iv) delivered by facsimile, with receipt
                  confirmed, to the Party at the address set forth below for
                  such Party:

<TABLE>
                <S>                               <C>
                  To Aventis:                      To Gene Logic:
                  Aventis CropScience GmbH         Gene Logic Inc.
                  Industriepark Hochst - K607      708 Quince Orchard Road
                  Bruningstrasse 50                Gaithersburg, Maryland 20878
                  D 65926 Frankfurt am Main        United States of America
                  Attention: General Counsel       Attention: President
                  Facsimile 49-69-305-834-54       Facsimile: 1-301-987-1701

                  With a copy to:
                  Aventis CropScience N.V.
                  Jozef Plateaustraat 22
                  B 9000 Gent
                  Belgium
                  Attention: General Counsel
                  Facsimile: 32-9-235-84-76
</TABLE>

                  or to such other address as to which the Party has given
                  written notice Thereof. Such notices shall be deemed given
                  upon receipt.

         6.2      Use of Names

                  Except as expressly provided in this Agreement, no Party shall
                  use the name of the other Party in any promotional materials
                  or advertising without the prior written consent of the other
                  Party.

                                      -3-
<PAGE>   4

         6.3      Headings

                  The headings appearing herein have been inserted solely for
                  the convenience of the Parties hereto and shall not affect the
                  construction, meaning or interpretation of this Agreement or
                  any of its terms and conditions.

         6.4      Entire Agreement

                  This Agreement constitutes the entire understanding of between
                  the Parties with respect to the subject matter contained
                  herein and supersedes any and all prior agreements,
                  understandings and arrangements whether oral or written
                  between the Parties relating to the subject matter hereof,
                  except the Collaboration Agreement as amended and terminated
                  by this Agreement.

         6.5      Amendments

                  Except as otherwise specifically provided in this Agreement,
                  no conditions, usage of trade, course of dealing or
                  performance, understanding or agreement purporting to modify,
                  vary, explain or supplement the terms or conditions of this
                  Agreement shall be binding unless hereafter made in writing
                  and signed by the Party to be bound and no modification shall
                  be effected by the acknowledgment or acceptance of documents
                  containing terms or conditions at variance with or in addition
                  to those set forth in this Agreement.

         6.6      Waiver

                  No waiver by any Party with respect to any breach or default
                  or of any right or remedy and no course of dealing or
                  performance shall be deemed to constitute a continuing waiver
                  of any other breach or default or of any right or remedy,
                  unless such waiver be expressed in writing signed by the Party
                  to be bound. Failure of a Party to exercise any right shall
                  not be deemed a waiver of such right or rights in the future.

         6.7      Counterparts

                  This Agreement may be executed in several counterparts, each
                  of which shall be deemed to be an original, all of which
                  together shall be deemed to be one and the same instrument.

                                      -4-
<PAGE>   5

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed in
duplicate by their duly authorized representatives as of the dale set forth
above.

Gene Logic Inc.                                      Aventis CropScience GmbH

  /s/ Philip L. Rohrer, Jr.                           /s/ Peter Henkel
------------------------------------                 -------------------------
By:  Philip L. Rohrer, Jr.                           By: Peter Henkel
Title: CFO                                           Title: CEO

                                                      /s/ Gunther Falcke
                                                     -------------------------
                                                     By: Gunther Falcke
                                                     Title: General Counsel

                                      -5-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}]]